Carla Manzitti

Genoa, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 32 publications

FUS::FLI1 Fusion Ewing Sarcoma in an Infant.

FUS::FLI1 Fusion Ewing Sarcoma in an Infant.

Journal: Pediatric blood & cancer

Published: July 14, 2026

Association Between Dinutuximab Beta Exposure and Post-End-of-Treatment Survival in Neuroblastoma: A Weighted Patient-Level Analysis of Three Clinical Studies.

Association Between Dinutuximab Beta Exposure and Post-End-of-Treatment Survival in Neuroblastoma: A Weighted Patient-Level Analysis of Three Clinical Studies.

Journal: Pediatric blood & cancer

Published: May 10, 2026

Evolution of robotic-assisted resection of pediatric neuroblastic tumors: a retrospective analysis.

Evolution of robotic-assisted resection of pediatric neuroblastic tumors: a retrospective analysis.

Journal: Updates in surgery

Published: May 02, 2026

Missense but mis-spliced: germline TP53 variant c.671A > C (p.E224A) and the path from uncertainty to pathogenicity.

Missense but mis-spliced: germline TP53 variant c.671A > C (p.E224A) and the path from uncertainty to pathogenicity.

Journal: Scientific reports

Published: March 09, 2026

Mapping Genomic Heterogeneity in Pediatric and Adolescent-Young Adult Sarcomas: Insights from the Italian SAR-GEN2016 and SAR-GEN_ITA Prospective Multicenter Trials.

Mapping Genomic Heterogeneity in Pediatric and Adolescent-Young Adult Sarcomas: Insights from the Italian SAR-GEN2016 and SAR-GEN_ITA Prospective Multicenter Trials.

Journal: Cancer research communications

Published: November 06, 2025

Dinutuximab beta versus historical controls in the treatment of relapsed neuroblastoma: unadjusted and adjusted indirect comparisons.

Dinutuximab beta versus historical controls in the treatment of relapsed neuroblastoma: unadjusted and adjusted indirect comparisons.

Journal: Frontiers in oncology

Published: October 30, 2025

Is There a Role for Mifamurtide in Nonmetastatic High-Grade Osteosarcoma? Results From the Italian Sarcoma Group (ISG/OS-2) and Spanish Sarcoma Group (GEIS-33) Trials.

Is There a Role for Mifamurtide in Nonmetastatic High-Grade Osteosarcoma? Results From the Italian Sarcoma Group (ISG/OS-2) and Spanish Sarcoma Group (GEIS-33) Trials.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 18, 2025

Dinutuximab Beta Versus Naxitamab in the Treatment of Relapsed/Refractory Neuroblastoma in Patients with Stable Disease, Minor Response or Partial Response and Disease in Bone or Bone Marrow: Systematic Review and Matching-Adjusted Indirect Comparison.

Dinutuximab Beta Versus Naxitamab in the Treatment of Relapsed/Refractory Neuroblastoma in Patients with Stable Disease, Minor Response or Partial Response and Disease in Bone or Bone Marrow: Systematic Review and Matching-Adjusted Indirect Comparison.

Journal: Cancers

Published: July 24, 2025

Diagnostic Delay and Survival in Pediatric Rhabdomyosarcoma: Is Time a Critical Factor?

Diagnostic Delay and Survival in Pediatric Rhabdomyosarcoma: Is Time a Critical Factor?

Journal: Journal of pediatric hematology/oncology

Published: April 18, 2025

Excellent Results in the Off-Label Use of Denosumab in Pediatric Oncology: Monocentric Case Series Study.

Excellent Results in the Off-Label Use of Denosumab in Pediatric Oncology: Monocentric Case Series Study.

Journal: Case reports in pediatrics

Published: February 06, 2025

Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial.

Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 17, 2025

Intensified Induction Therapy for Newly Diagnosed, Localized Skeletal Ewing Sarcoma (ISG/AIEOP EW-1): A Randomized, Open-Label, Phase 3, Non-Inferiority Trial.

Intensified Induction Therapy for Newly Diagnosed, Localized Skeletal Ewing Sarcoma (ISG/AIEOP EW-1): A Randomized, Open-Label, Phase 3, Non-Inferiority Trial.

Journal: Pediatric blood & cancer

Published: October 04, 2024

Showing 1-12 of 32

Last Updated: 09/26/2026